Acromegaly Enrollment Form



Fax Referral To: 1-800-323-2445

Phone: 1-800-237-2767 Email Referral To: Customer.ServiceFax@CVSHealth.com

Six Simple Steps to Submitting a Referral PATIENT INFORMATION (Complete or include demographic sheet) Address: Preferred Contact Methods: Phone (to primary # provided below) Text (to cell # provided below) Email (to email provided below) Note: Carrier charges may apply. By providing the phone number(s) and email address above, you are consenting to receive automated calls, emails and/or text messages from CVS Specialty® about your prescription(s), account, and health care. Standard data rates apply. Message frequency varies. If unable to contact via text or email, Specialty Pharmacy will attempt to contact by phone. Primary Phone: _____ ____ Alternate Phone: __ Email: _____Last Four of SSN: _____ Primary Language: ______ Parent/Caregiver/Legal Guardian Name (Last, First): Relationship to patient: 2 PRESCRIBER INFORMATION Prescriber's Name: _____ State License #: NPI #: _____ DEA #: ____ Group or Hospital: ___ Address: _____ City, State, ZIP Code: _____ _____Fax_____Contact Person: _____Contact's Phone: _____ Phone: 3 INSURANCE INFORMATION Please fax copy of prescription and insurance cards with this form, if available (front and back)
4 DIAGNOSIS AND CLINICAL INFORMATION Ship to: Patient Office Other: Needs by Date: Diagnosis (ICD-10): Other Code: _____ Description: _____ E22.0 acromegaly and pituitary giantism **Patient Clinical Information:** Height: _____in/cm Alleraies: Weight: ____lb/kg 5 PRESCRIPTION INFORMATION **DOSE & DIRECTIONS QUANTITY/REFILLS MEDICATION STRENGTH** ☐ 1 pen ☐ 2 pens ☐ Administer ____ mcg SC three times a day ☐ Bynfezia Pen (octreotide ☐ Other: _____ 2,500 mcg/mL acetate) injection Refills: ☐ 60 mg prefilled syringe 4-week supply ☐ Inject 90 mg (1 syringe) SC every 4 weeks ☐ Lanreotide Injection ☐ 90 mg prefilled syringe ☐ 12-week supply Other: Inject _____ mg (1 syringe) SC every 4 weeks Refills: ___ ☐ 120 mg prefilled syringe Quantity: _____ ☐ 50 mcg/mL Administer ____ mcg SC three times a day ☐ Sandostatin Injection Refills: _____ 100 mcg/mL Ampules Other: ☐ 500 mcg/mL Administer ____ mcg SC three times a day Quantity: _____ ☐ Sandostatin Injection 200 mcg/mL (5 ml) Refills: _ ☐ Other: Multi-dose Vials ☐ 1,000 mcg/mL (5 ml) 10 mg vial kit Mix the contents of one vial with diluent and administer 4-week supply ☐ Sandostatin LAR Depot 20 mg vial kit intragluteally every 4 weeks ☐ 12-week supply Refills: _ 30 mg vial kit Other: 4-week supply ☐ 60 mg prefilled syringe ☐ Inject 90 mg (1 syringe) SC every 4 weeks ☐ 12-week supply ☐ Somatuline Depot ☐ 90 mg prefilled syringe ☐ Other: Inject _____ mg (1 syringe) SC every 4 weeks Refills: ☐ 120 mg prefilled syringe 10 mg vial kits ☐ 10 mg vial 15 mg vial kits
20 mg vial kits ☐ 15 mg vial ☐ Inject____mg SC once daily ☐ Somavert 20 mg vial \square 25 mg vial Refills: 30 mg vial STAMP SIGNATURE NOT ALLOWED Ancillary supplies and kits provided as needed for administration Patient is interested in patient support programs **TPRESCRIBER SIGNATURE REQUIRED (STAMP SIGNATURE NOT ALLOWED)** "Dispense As Written" / Brand Medically Necessary / Do Not Substitute / No Substitution / May Substitute / Product Selection Permitted / DAW / May Not Substitute Substitution Permissible Prescriber's Signature:_ Prescriber's Signature:_

CA, MA, NC & PR: Interchange is mandated unless Prescriber writes the words "No Substitution" ____ ATTN: New York and Iowa providers, please submit electronic prescription The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the patient's medical record. By signing above, I hereby authorize CVS Specialty Pharmacy and/or its affiliate pharmacies to complete and submit prior authorization (PA) requests to payors for the prescribe dimedication for this patient and to attach this Enrollment Form to the PA

request as my signature.

CONFIDENTIALITY NOTICE: This communication and any attachments may contain confidential and/or privileged information for the use of the designated recipients named above. If you are not the intended recipient, you are hereby notified that you have received this communication in error and that any review, disclosure, dissemination, distribution or copying of it or its contents is prohibited. If you have received this communication in error, please notify the sender immediately by telephone and destroy all copies of this communication and any attachments.

Plan member privacy is important to us. Our employees are trained regarding the appropriate way to handle members' private health information.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Specialty and/or one of its affiliates.